ABBV
AbbViePrevious close
294.89
Change
+4.10 / +1.41%
Market Cap
$522B
1M
+12.73%
S&P 500 −0.91% over same period
Volume / Avg Volume
6.9M / 4.4M
1.56× average
Latest earnings analysisFY2026 Q2Reported 2026-07-06
AbbVie Q2 FY2026: revenue up 10.2%, adjusted EPS $3.65
Revenue grew 10.2% and GAAP gross margin jumped to 74.7%, but adjusted EPS of $3.65 came in just under the $3.6761 consensus, and full-year guidance was trimmed by $0.04 at the midpoint. Read this quarter in two layers: the operating business in immunology and neuroscience is compounding, while the GAAP-to-adjusted gap and the pending $10.9 billion Apogee acquisition explain most of the noise.
Read the full analysis →Revenue$16.99BYoY +10.20%
EPS (non-GAAP)$3.65Missest. $3.68
Next-day move−0.04%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-06 | $17.0B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-03 | $15.0B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-07 | $61.2B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-03 | $15.8B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 62 of its 5-year rangeMid-range
5-year range 30.7 – 169.0 · Median 73.9
Last 4 quarters: $1.5B in buybacks + $12.0B in dividends, 2.58% of market cap combined
P/E (TTM)
81.4
P/B
—
P/S
8.0
Dividend Yield
4.47%
Earnings Reaction
Over the last 4 reports, the stock moved ±1.7% on average on the first trading day after, rising 0 times
Most recent −0.04%
Volatility & Correlation
1-year beta -0.17 · Correlation with S&P 500 -0.08Low beta
Annualized volatility 26% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 1 · $8.2MNet selling $8.2M
- 08-14Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERSell$8.2M32,710 shares · Avg price 250.00
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 16.99 | +10.2% | 74.7% | 3.61 | 2.03 |
| FY2026 Q1 | 15.00 | +12.4% | 71.9% | 0.70 | 0.39 |
| FY2025 Q4 | 16.62 | +10.0% | — | 1.82 | 1.02 |
| FY2025 Q3 | 15.78 | +9.1% | 66.4% | 0.19 | 0.10 |
| FY2025 Q2 | 15.42 | +6.6% | 71.8% | 0.94 | 0.52 |
| FY2025 Q1 | 13.34 | +8.4% | 70.0% | 1.29 | 0.72 |
| FY2024 Q4 | 15.10 | +5.6% | — | -0.02 | -0.02 |
| FY2024 Q3 | 14.46 | +3.8% | 70.9% | 1.56 | 0.88 |
| FY2024 Q2 | 14.46 | +4.3% | 70.9% | 1.37 | 0.77 |
| FY2024 Q1 | 12.31 | +0.7% | 66.7% | 1.37 | 0.77 |
| FY2023 Q4 | 14.30 | −5.4% | — | 0.82 | 0.46 |
| FY2023 Q3 | 13.93 | −6.0% | 53.4% | 1.78 | 1.00 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |
| ABT | 39.1 | +7.8% | 56.2% | +7.46% | Neutral |